share_log

复星医药(02196):复星医药产业及Kite Pharma拟根据各自所持复星凯特的股权比例向其续展及新增提供总额不超过等值6700万美元的借款

Fosun Pharmaceutical (02196): Fosun Pharmaceutical Industries and Kite Pharma plan to renew and provide additional loans totaling no more than 67 million US dollars to Fosun Kate based on their respective shareholding ratios

Zhitong Finance ·  Apr 29 06:46

Fosun Pharmaceutical (02196) issued an announcement to satisfy Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as “Fosun Kate...

Zhitong Finance App News, Fosun Pharmaceutical (02196) announced that in order to meet the business plans and capital requirements of Fosun Kate Biotechnology Co., Ltd. (hereinafter referred to as “Fosun Kate”), it is proposed to request the shareholders' meeting of the company's shareholders' approval for the holding subsidiary Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”) and Kite Pharma, Inc. (hereinafter referred to as “Kite Pharma”), the other shareholder of Fosun Kate, to renew and add no more than the total equivalent value of Fosun Kate according to their respective shares in Fosun Kate A loan of 67 million US dollars (including principal amount) (including direct loans or entrustment loans, etc., same below). Of these, Fosun Pharmaceutical Industries plans to provide it with a loan of no more than 33.5 million US dollars (including principal amount) according to the shareholding ratio (that is, 50%).

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment